TNM Classification of Malignant Tumours

A cancer-staging notation that separately codes the anatomical extent of the primary tumor, regional lymph-node involvement, and distant metastasis under site-, histology-, evidence-, and edition-specific rules, then optionally groups those codes into prognostic stages.

Version

v1 · 2026-09-28 · History

Domain-specific #

7785

Domain group

Applied Sciences & Engineering

Origin domain

Medicine & Healthcare

Subdomain

Oncology → Medicine & Healthcare

Aliases

TNM Staging System, TNM Classification, AJCC UICC Staging System

Core Idea

The TNM Classification of Malignant Tumours is a governed notation for describing the anatomical extent of many cancers.^[1] It records three partly independent dimensions: T describes the primary tumor, N describes involvement of regional lymph nodes, and M describes distant metastasis.^[2] Site- and tumor-specific rules assign category values, and combinations may be mapped into stage groups for prognosis, treatment planning, research stratification, and registry comparison.

TNM is not one universal ladder applied identically to every malignancy. The meaning of T1, N2, or another category depends on primary site, histology, edition, and sometimes additional factors.^[3] For one cancer T may be governed by size; for another it may depend on depth, invasion of named structures, multiplicity, or organ confinement. A code without its classification context is incomplete.

The T axis describes the primary tumor's anatomical extent. Common symbols include TX when the tumor cannot be assessed, T0 when no evidence of a primary tumor is found, Tis for carcinoma in situ where applicable, and increasing numbered categories. Those familiar forms are a grammar, not a guarantee that every site uses every value or the same thresholds.

The N axis records regional-node involvement under the drainage regions and evidence rules defined for that cancer.^[4] Category can depend on number, location, laterality, size, extranodal extension, sentinel-node findings, or other site-specific features. Regional nodes must be distinguished from distant nodal metastasis.

The M axis records absence or presence and, for some cancers, subclassification of distant metastatic spread. M0 and M1 are not merely logical complements under all evidence routes: the rules for assigning clinical and pathological M categories differ, and pathological confirmation conventions matter.^[5] A reviewer must retain prefixes and evidence basis.

Prefixes identify how the classification was obtained. cTNM is based on evidence available before definitive treatment, including examination, imaging, endoscopy, biopsy, and other permitted studies. pTNM incorporates pathological examination after surgical treatment under specified adequacy rules. Other prefixes and descriptors can indicate recurrence, autopsy, neoadjuvant treatment, multiplicity, or uncertainty. Removing a prefix can collapse distinct claims.

Category assignment and stage grouping are separate operations.^[6] T, N, and M describe anatomical extent. A stage group, often numbered I through IV with subdivisions, combines categories and may incorporate prognostic factors according to the cancer-specific schema. Two patients can share a broad stage group while having different TNM patterns and clinical implications.

TNM is primarily anatomical, although modern schemas may supplement anatomy with biomarkers, grade, age, molecular features, or other prognostic information. Such additions should not be allowed to obscure what the core code means. Anatomical stage, clinical prognostic stage, and pathological prognostic stage may be different products.

The system is versioned. The frozen Wikipedia text called the eighth edition of 2017 the latest. UICC published the ninth edition in 2025 and recommended it take effect on 1 January 2026.^[7] A valid record must name edition and implementation date because definitions can change.^[8] Longitudinal or multi-registry comparisons require mapping or stratification rather than silently treating codes from different editions as identical.

UICC and AJCC coordinate closely, but their manuals, jurisdictional adoption, timing, and supplementary rules should not be assumed perfectly interchangeable in every use.^[9] FIGO staging for gynecologic cancers and other disease-specific systems may align with TNM while retaining their own governance. “AJCC/UICC” is a useful surface, not a license to erase source authority.

TNM does not cover every cancer. Hematologic malignancies, many central-nervous-system tumors, pediatric cancers, and other entities may use different staging or risk-classification systems. Even within solid tumors, eligibility depends on the manual's declared site and histology. The absence of a TNM code is not the absence of severity.

The classification describes extent at a defined time and evidence state. It does not directly encode symptoms, treatment response, comorbidity, performance status, tumor biology, patient preference, or expected survival. Those variables can be clinically decisive. Stage contributes to judgment rather than replacing it.

Reclassification can occur because new evidence appears, rules change, or data are corrected. This is not necessarily biological progression. Researchers must distinguish change in disease state from change in observation or coding frame. Registries preserve source, date, edition, and basis to maintain comparability.

Structural Signature

Sig role-phrases:

• the governing classification — a named UICC or AJCC manual, edition, and implementation context supply the applicable rules.
• the eligible malignancy — primary site and histology place the cancer inside the declared manual's scope before any TNM category is assigned.
• the assessment state — time point, available evidence, and clinical, pathological, post-treatment, recurrent, or other recognized prefix type the claim.
• the T axis — site-specific criteria assign the anatomical extent of the primary tumor, including distinct unassessed, absent, in-situ, and numbered branches where defined.
• the N axis — the cancer-specific regional-node map and evidence rules assign nodal involvement without conflating regional and distant nodes.
• the M axis — permitted evidence assigns absence, presence, or an applicable subclass of distant metastatic spread.
• the qualified TNM tuple — prefixes, suffixes, multiplicity markers, and uncertainty descriptors remain attached to the three categories rather than being discarded.
• the stage-group relation — a governed table may map the typed tuple, and sometimes declared prognostic factors, into a broader stage group without making the group identical to TNM.
• the provenance relation — source examinations, imaging, pathology, date, and edition make reclassification distinguishable from biological progression.
• the assignment boundary — only a manual-eligible malignancy classified under its site-, histology-, evidence-, and edition-specific TNM rules qualifies; another staging scheme or a bare severity label does not.

What It Is Not

• Not a single linear severity score. T, N, and M classify different anatomical dimensions under site-specific rules, and their symbols are not interchangeable quantities that can simply be added or ranked across cancers.

• Not synonymous with a stage group. A stage-group table compresses a qualified TNM tuple—and sometimes declared prognostic factors—under further rules; the grouped result does not replace the underlying categories.

• Not universal across all malignancies. Eligibility depends on the governing manual, primary site, and histology; leukemias, many central-nervous-system tumors, pediatric cancers, and other entities may use different systems.

• Not timeless across editions or authorities. Category definitions, groupings, prefixes, and implementation dates can change, so a bare code without manual, edition, jurisdiction, and date is underspecified.

• Not permission to treat unknown as negative. TX or NX records an assessment limit, whereas T0 or N0 makes a governed finding; unavailable evidence cannot be silently converted into absence.

• Not a complete prognosis or treatment prescription. Anatomical extent does not directly encode tumor biology, symptoms, comorbidity, performance status, treatment response, or patient preference.^[10]

• Not proof that identical codes imply identical disease or outcome. The same tuple can occur with different molecular features, evidence routes, time points, and clinical contexts, while reclassification may reflect new evidence or rule changes rather than biological progression.

Scope of Application

The TNM Classification is a precondition-bounded oncology instrument: it applies only to a malignancy included by the governing manual for the declared primary site, histology, edition, jurisdiction, assessment time, and evidence route. Its habitats use the typed T/N/M tuple or an explicitly governed stage-group mapping; a bare stage label outside those conditions is not a TNM application.^[11]

• Pretreatment clinical assessment. cTNM organizes permitted examination, imaging, endoscopy, biopsy, and related evidence into site-specific primary-tumor, regional-node, and distant-metastasis categories before definitive treatment.
• Postsurgical pathological assessment. pTNM applies when resection and pathological examination satisfy the manual's adequacy rules, preserving a different evidence basis rather than silently replacing cTNM.
• Cancer-site multidisciplinary care. Teams use the qualified tuple and, where applicable, stage group to communicate anatomical extent while keeping grade, biomarkers, performance status, comorbidity, response, and preference outside the code.
• Cancer-registry abstraction. Registries record site, histology, source evidence, prefix, date, edition, and authority so codes remain interpretable and recoding can be distinguished from disease progression.
• Clinical-trial eligibility and stratification. Protocols may use declared TNM categories or stage groups to define cohorts, but eligibility must bind the cancer-specific schema and cannot treat like-numbered categories across sites as commensurable.
• Cancer epidemiology and population statistics. Incidence, survival, and stage-distribution comparisons are legitimate when edition, implementation date, case mix, missingness, and registry rules are aligned or explicitly mapped.
• Prognostic research. TNM supplies an anatomical predictor or grouping input; it does not by itself constitute a complete prognosis when biology and patient-level covariates remain unmodeled.^[12]
• Longitudinal and cross-edition comparison. Repeated classifications can be compared only after separating biological change from new evidence, correction, altered prefixes, or revised category definitions.
• Eligible adult solid tumors. Many site- and histology-defined carcinomas and other solid malignancies have TNM chapters, whereas hematologic malignancies, many central-nervous-system tumors, pediatric cancers, and other excluded entities require their own governed systems.
• Coordination with related staging authorities. UICC, AJCC, FIGO, and local adoption practices can align in specified contexts, but their manuals and implementation rules must be identified rather than presumed interchangeable.

Clarity

Naming the TNM classification makes visible the structured anatomical claim hidden by the loose word “stage.” It separates the primary-tumor category, regional-node category, and distant-metastasis category from the later stage-group mapping, and it preserves the evidence route carried by prefixes such as c and p. It also prevents unknown or unassessed findings from being read as negative: TX is not T0, and NX is not N0.

The notation sharpens another crucial distinction: category labels share a grammar without being commensurable measurements across cancers or editions. T2 for one primary site need not describe the same anatomy as T2 for another, and an identical-looking code can change meaning when its histology, governing manual, or edition changes. The better clinical or registry question is: which site- and histology-specific rules, edition, assessment time, evidence prefix, and underlying T/N/M tuple support this reported classification or stage group?

Manages Complexity

TNM compresses the heterogeneous anatomical evidence for an eligible malignancy into a typed tuple: primary-tumor extent T, regional-node involvement N, and distant metastasis M. The analyst tracks the tumor's site and histology, the governing edition, the assessment time and evidence prefix, and the three assigned categories. Governed tables can then map that tuple to a broader stage group. This separates useful branches that a single stage number would hide: two cancers may share a stage group but differ in T and N; cTNM and pTNM may describe the same person from different evidence bases; and TX or NX preserves inability to assess rather than falsely recording absence.

The compression stops at the local rulebook and provenance boundary. Category numbers are not commensurable across primary sites, histologies, editions, or clinical and pathological routes, while biomarkers and prognostic factors may enter some stage-group products without changing the core anatomical tuple. A changed code may reflect new evidence, recoding, or a revised manual rather than disease progression. TNM therefore makes extent portable only when the full type, prefix, date, source evidence, and edition travel with it; it does not encode tumor grade, symptoms, response, comorbidity, patient preference, or a treatment decision.

Abstract Reasoning

Classification begins from a fully typed case, not from three free-standing numbers. The assessor first fixes primary site, histology, governing edition, assessment time, and evidence route, then applies the corresponding rules to observations about primary-tumor extent, regional nodes, and distant spread. The result is a prefixed T/N/M tuple whose components preserve negative findings, positive findings, and inability to assess as different states. An identical-looking category in another cancer or edition cannot be carried over without reopening those typing decisions.

Stage grouping is a second inference. A governed table maps the typed tuple—and, where the specified product requires them, additional prognostic factors—into a broader group. This many-to-one mapping supports prognosis or cohort stratification while predicting loss of anatomical detail: two cases in the same group may reach it through different T and N patterns. When a treatment or registry question depends on those differences, reasoning must return to the tuple and source observations rather than treating the group as the disease itself.

Discrepancy and longitudinal analysis require competing explanations. A change from cTNM to pTNM may reflect stronger pathological evidence rather than biological progression; a changed code across editions may reflect a revised rule; correction of a regional-node map may be recoding. Comparing dates, prefixes, source studies, and manuals separates those branches. A distant node outside the site-specific regional basin, for example, changes the M reasoning rather than merely incrementing N. The system therefore supports bounded predictions about anatomical extent under its declared manual, but it does not infer tumor grade, treatment response, comorbidity, patient preference, or outcome from the code alone.

Knowledge Transfer

Within oncology, TNM transfers literally across eligible primary sites, clinical care, pathology, cancer registries, epidemiology, and trial stratification only when the governing site, histology, edition, assessment time, and evidence route accompany the code. The carried mechanism separately assigns T, N, and M under local rules and then, when appropriate, maps the typed tuple to a stage group. Its diagnostics preserve unknown versus negative states, regional versus distant nodes, category tuple versus stage group, and biological progression versus recoding after new evidence or an edition change. Its practical interventions are classification operations—retrieve the correct manual, correct the tumor type or nodal map, add the c or p prefix, retain source evidence, and remap rather than treating superficially identical category numbers as universal measurements.

Beyond cancer staging, the honest transfer is (B) shared abstract mechanism through Classification, with an (A) analogy boundary. Other governed staging systems may likewise decompose extent into typed, partially independent dimensions and compress the resulting tuple for communication or decisions. What travels is the versioned multidimensional-classification pattern; what remains home-bound is malignant-tumor anatomy, primary site and histology, regional lymphatics, distant metastasis, cTNM and pTNM evidence rules, and UICC/AJCC manuals. A maturity model or project “stage” can borrow the three-axis idea only as analogy, and even many cancers fall outside TNM's scope. The stopping boundary is the loss of an eligible malignancy under the applicable manual; beyond it, only the general Classification lesson remains.

Examples

Canonical

This is a schematic tuple, not a portable staging rule. Assume a malignancy whose specified primary site and histology are eligible under a named tumor chapter, manual, and edition, and assume that chapter defines the documented small localized primary as T1. A pathologically examined resection may then be recorded as pT1 pN0 M0 when the specimen supports that primary-tumor category, finds no qualifying regional-node involvement, and the permitted evidence supports M0. If the same chapter's governed table maps that exact tuple to stage I, the conditional stage-group result is stage I for that specified cancer under that edition. The prefix and tuple remain essential: p identifies the pathological evidence route, N0 is not NX, and the stage group is a many-to-one summary rather than a replacement for the anatomical categories. The same symbols cannot be transferred to another primary site or edition without reopening its rules.

Mapped back: The assumed named manual, chapter, and edition are the governing classification, and the explicitly assumed site and histology establish the eligible malignancy for this schematic case. The p prefix records the assessment state; T1, pN0, and M0 instantiate the T axis, the N axis, and the M axis only under those local rules. Their prefixed combination is the qualified TNM tuple, while the conditional lookup in that chapter's table is the stage-group relation.

Applied / In Practice

A cancer registry may receive a pretreatment cTNM record based on examination and imaging and later a pTNM record after surgical pathology. The registrar preserves both classifications with their dates, sources, edition, and cancer-specific rules instead of overwriting the earlier record. If the categories differ, the discrepancy may reflect the stronger evidence route rather than biological progression. When cases collected under different TNM editions are compared, the registry maps or stratifies them explicitly; it does not assume that identical-looking codes have unchanged definitions. These classifications describe anatomical extent and do not by themselves prescribe treatment or determine an individual's prognosis.

Mapped back: Clinical and pathological records preserve distinct instances of the assessment state, and their prefixes remain in the qualified TNM tuple. Dates, source examinations, pathology, and edition instantiate the provenance relation, allowing evidence-driven reclassification to be distinguished from progression. Requiring a manual-eligible cancer and its local rule set enforces the assignment boundary.

Structural Tensions

T1: Compact stage group versus retained anatomical detail. A stage group makes complex extent easier to communicate and compare, but its many-to-one mapping can hide materially different T, N, and M patterns. Retaining only the group defeats the system's decomposition, whereas retaining every observation weakens the value of the compression.

Diagnostic: Does the use preserve the qualified T/N/M tuple whenever a decision or comparison could depend on distinctions erased by the stage group?

T2: Shared notation versus cancer-specific meaning. The common T/N/M grammar supports coordination across oncology, yet each category receives meaning from a particular primary site, histology, and edition. Reading category numbers as universal measurements gains superficial comparability by discarding the conditions that make them valid.

Diagnostic: Are like-looking categories compared only after their site-, histology-, and edition-specific definitions have been aligned or explicitly mapped?

T3: Anatomical extent versus broader clinical significance. TNM deliberately isolates anatomical extent, which makes the classification coherent, while prognosis and care can also depend on biology, grade, response, comorbidity, and patient circumstances. Adding every relevant factor to the core tuple would blur its identity; treating the tuple as sufficient would overstate it.

Diagnostic: Is TNM being used as a bounded anatomical input while clinically decisive factors outside that input remain separately visible?

T4: Clinical evidence versus pathological evidence. cTNM supplies a pretreatment classification when decisions cannot await definitive pathology, whereas pTNM can refine extent through postsurgical examination. Collapsing the two loses evidence provenance, but treating their difference automatically as disease change mistakes a change of observation basis for a biological event.

Diagnostic: Are clinical and pathological classifications retained with their prefixes, dates, and evidence sources rather than overwritten or read as a progression sequence?

T5: Stable longitudinal coding versus revised rules. Edition changes can improve category definitions and prognostic grouping, yet they can also make historical and current codes non-equivalent. Freezing an old rule preserves comparability at the cost of current validity; silently recoding destroys the record of which rule originally governed the claim.

Diagnostic: Does a longitudinal comparison identify each governing edition and distinguish mapped recoding from a change in the malignancy's observed extent?

T6: Decisive categories versus explicit uncertainty. The notation supports definite branches such as T0 or N0, but it must also preserve states such as TX or NX when assessment is insufficient. Forcing every case into a definite category improves apparent completeness by converting an evidence limit into a false negative.

Diagnostic: Does the assignment distinguish inability to assess from a governed finding of absence, with the evidence basis sufficient for the branch selected?

T7: International standardization versus authority-specific governance. Coordination between UICC, AJCC, FIGO, and local adopters promotes shared communication, while manuals, implementation dates, and supplementary rules need not be interchangeable in every setting. Treating the joint surface as one timeless authority erases the governance needed to interpret a code.

Diagnostic: Is the responsible manual, edition, jurisdiction, and implementation context named wherever an authority difference could alter classification or grouping?

T8: TNM autonomy versus reduction to Classification (Classification). The parent Prime carries the portable structure of assigning typed cases to governed categories. Every TNM staging assignment is a strict kind of Classification, but TNM remains an oncology specialization because its three anatomical axes, regional-node maps, evidence prefixes, eligible malignancies, and editioned manuals determine valid assignment in situ. Reduction loses those constitutive rules; treating TNM as wholly autonomous hides the general classificatory carrier.

Diagnostic: Does the account retain TNM's cancer-specific axes, evidence routes, eligibility rules, and governance as the differentia of this Classification?

Structural–Framed Character

TNM is framed-leaning because a stable classificatory operation is present, yet the identity of every valid code is fixed by an editioned oncology rule system. Its evaluative_weight is low: T, N, and M neutrally classify anatomical extent, while severity, prognosis, and treatment consequences arise downstream and must not be read back into the tuple. It is strongly human_practice_bound, since without the acts of clinical or pathological assessment, rule application, prefixing, and registry or care communication there is disease anatomy but no TNM classification. Its institutional_origin is decisive because named authorities, manuals, editions, site chapters, and implementation contexts constitute the available categories and mappings. Its vocab_travels poorly: entity, criterion, and assignment are portable, whereas T/N/M axes, cTNM and pTNM prefixes, regional-node maps, and stage-group tables retain their referents only within governed cancer staging. On import_vs_recognize, another versioned multidimensional code may instantiate the same classificatory structure, but it is not literally TNM unless an eligible malignancy is assigned under the applicable oncology rules.

The smallest reviewed portable skeleton is Classification: typed entities are tested against explicit criteria and assigned to reusable categories. The cross-domain reach belongs to that Prime. TNM keeps home-bound the eligible malignancy, primary-site and histology typing, anatomical T/N/M dimensions, evidence route, manual edition, and the separately governed mapping from tuple to stage group.

Its character: framed-leaning because rule-based classification is portable while institutional governance and cancer-specific anatomy constitute every TNM identity.

Structural Core vs. Domain Accent

This decomposition explains why the TNM Classification of Malignant Tumours is a domain-specific abstraction rather than a Prime.

What is skeletal (could lift toward a cross-domain prime). Typed entities are evaluated against explicit criteria, a governed assignment rule places them in reusable categories, and those categories support downstream comparison or action while preserving unknown and boundary states. The invariant is reproducible entity–criterion–assignment–category organization, and recognition fails when labels lack rules or when assignment becomes informal grouping. TNM is therefore a strict specialization of Classification: Classification supplies the complete sorting structure, while TNM fixes the entity type, dimensions, evidence routes, and rule authority.

What is domain-bound. The entity is an eligible malignancy typed by primary site and histology under a named manual and edition. Clinical or pathological evidence separately assigns primary-tumor extent, regional-node involvement, and distant metastasis to a qualified T/N/M tuple; prefixes and provenance remain attached, and a second governed mapping may compress the tuple into a stage group. Unknown is not negative, like-numbered categories are not commensurable across cancer sites, and the anatomical tuple does not itself encode prognosis, treatment, or tumor biology. These oncology and governance conditions constitute the identity.

Why this does not clear the prime bar. The complete malignancy-eligibility, site-and-histology, T/N/M-axis, evidence-prefix, edition-governance, qualified-tuple, and stage-group-mapping signature does not recur literally across at least three unrelated domains with the same recognition and failure conditions. Knowledge Transfer assigns governed multidimensional sorting to Classification; another staging scheme may share that mechanism, but it is not TNM without the cancer-specific manual and anatomy. Removing the oncology accent leaves a versioned Classification but not TNM, while removing explicit criteria and governed assignment leaves anatomical observations or shorthand symbols without the classificatory operation that makes them a valid TNM tuple.

Instantiates / Related Primes

This entry is a kind of Classification.

Instantiates — Classification (Classification). The eligible malignancy is the entity to be sorted; the governing manual supplies explicit site-, histology-, evidence-, and edition-specific criteria; and the T, N, and M rules assign it to a qualified tuple of discrete categories. That tuple becomes a reusable map for comparison and may feed a separate governed stage-group mapping. Unknown and negative states, clinical and pathological evidence routes, and edition provenance show that TNM is rule-bound assignment rather than informal severity grouping. If those criteria and assignment rules were removed, T/N/M symbols would no longer support reproducible category membership or downstream staging, collapsing both TNM's identity and Classification's entities→criteria→assignment→category structure. The anatomical axes and oncology governance are TNM's domain-specific residual.

Relationships to Other Abstractions

Current abstraction TNM Classification of Malignant Tumours Domain-specific

Parents (1) — more general patterns this builds on

• TNM Classification of Malignant Tumours is a kind of Classification Prime

  The eligible malignancy is the entity to be sorted; the governing manual supplies explicit site-, histology-, evidence-, and edition-specific criteria; and the T, N, and M rules assign it to a qualified tuple of discrete categories.

Hierarchy path (1) — routes to 1 parentless root

• TNM Classification of Malignant Tumours → Classification

Neighborhood in Abstraction Space

TNM Classification of Malignant Tumours sits in a sparse region of the domain-specific corpus (92^nd percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Unclustered & Miscellaneous (2551 abstractions)

Nearest neighbors

• Continuous Individualized Risk Index — 0.81
• Sequencing Coverage — 0.80
• Equivalent Dose — 0.79
• Length time bias — 0.79
• Diagnostic Method — 0.79

Computed from structural-signature embeddings · 2026-10-08

Not to Be Confused With

• Cancer Stage Group. A cancer stage group compresses site-specific T, N, and M categories, and sometimes additional prognostic factors, into a broader ordinal stage; it is an output derived from TNM rather than the category system itself. Tell: a Roman-numeral or grouped stage is a stage group, while separately assigned anatomical T, N, and M categories are TNM.
• Tumor Grade. Tumor grade describes microscopic differentiation or related biological appearance, whereas TNM classifies anatomical extent. Tell: histologic appearance establishes grade; primary-tumor extent, regional nodes, and distant metastasis establish TNM categories.
• Clinical TNM. Clinical TNM is the pretreatment evidence route marked by the c prefix and is one qualified application of the TNM system. Tell: categories based on clinical examination, imaging, and other pretreatment evidence carry c, rather than the postsurgical p evidence route.
• Pathological TNM. Pathological TNM is the postsurgical evidence route marked by p and may refine the anatomical categories using resection evidence. Tell: the prefix and evidence provenance—not simply a different number—distinguish pathological from clinical TNM.
• FIGO Staging. FIGO staging is a separately governed gynecologic cancer-staging system that may be aligned with TNM in specified settings but retains its own rules. Tell: identify the issuing scheme and site-specific rule set rather than treating a numerically similar FIGO label as a TNM category.
• Response Assessment. Response assessment measures change during or after treatment, while TNM records anatomical extent under a declared staging time and evidence route. Tell: comparison with a treatment baseline identifies response; assignment of T, N, and M anatomy identifies staging.
• Risk Score. A risk score predicts an outcome from multiple variables and may include TNM stage as one input; TNM itself is a neutral anatomical classification. Tell: a weighted probability or prognostic estimate is a risk score, while categorical anatomy without the prediction model is TNM.
• Secondary Malignant Neoplasm. A secondary malignant neoplasm is a metastatic lesion or diagnosis, not the classification system that records distant spread. Tell: tissue or disease at a distant site is the lesion; the M category is the standardized statement about its status within TNM.

References

[1] TNM Classification of Malignant Tumours registry ↩ Show verification details

[2] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[3] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[4] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[5] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[6] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[7] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[8] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[9] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[10] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[11] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[12] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩